{"database": "lobbying", "table": "lobbying_activities", "rows": [[1739311, "201231ef-fd99-4117-94b4-670d042f26d3", "Q3", "BROWN RUDNICK LLP", 287895, "AMNEAL PHARMACEUTICALS", 2015, "third_quarter", "PHA", "Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94); Issues relating to abuse deterrent drug development", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2015-10-19T14:17:07.727000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1739311"], "units": {}, "query_ms": 24.94131401181221, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}